Verastem (VSTM) Other financing activities (2025 - 2026)
Verastem's quarterly Other financing activities came in at $700000.0 in Q1 2026, little changed year-on-year from $700000.0 in Q1 2025, and little changed quarter-over-quarter from $700000.0 in Q1 2025.
Verastem has reported Other financing activities for 2 years, with the latest figure at $700000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities changed 0.0% year-over-year to $700000.0; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $800000.0, changed N/A from the prior year.
- Other financing activities for Q1 2026 stood at $700000.0, roughly flat from $700000.0 in the prior quarter.
- The five-year high for Other financing activities was $700000.0 in Q1 2025, with the low at $700000.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Mar 31, 2025 | 700,000.00 |